Lviv clinical bulletin 2017, 1(17): 26-31

https://doi.org/10.25040/lkv2017.01.026

Chronic Lymphocytic Leukemia in Elderly Patients: Own Experience

Posted onAuthorAdminЗалишити коментар / Leave a comment

O. Vyhovska, Ya. Vyhovska, O. Shalay, L. Lukavetskyy, V. Voytsitskyy, L. Shevchenko, V. Barilka, Z. Maslyak

State Institution “Institute of Blood and Transfusion Medicine of NAMS of Ukraine”, Lviv

Introduction. The annual incidence rate of chronic lymphocytic leukemia (CLL) in Europe is 1­4 per 100 000 population. The disease is more common in older patients. For many years treatment of CLL included single­agent chlorambucil or cyclophosphamide, later ­ a combination of vincristine, cyclophosphamide, prednisolone (COP) alone or with addition of doxorubicin (CHOP) was used. In recent years, the arsenal of antileukemic agents has expanded significantly (fludarabine, cladribine, bendamustine, rituximab and others), a combination of these me­ dications provides a high percentage of complete remissions, but because of its immunosuppressive effect, this treatment cannot be used in all patients. In particular, in patients with comorbidities and older patients. Therefore a considerable attention has been recently paid to the management of the older patients with CLL.

The purpose of the study was to analyze the timeliness of CLL diagnosis and management of elderly patients according to data of the Consultative Polyclinics of SI “Institute of Blood Pathology and Transfusion Medicine NAMS of Ukraine”.

Results and discussion. 114 CLL patients aged from 61 to 86 were recruited in the study. More than 1/3 of patients were diagnosed with CLL in the late stages of the disease course (III­IV Rai stage), which emphasizes the insufficient wariness for hematological disorders among family doctors and other medical specialists. Results of 2­20 years long observation show that the majority of the patients whose diagnosis was made on early stage (0­I Rai stage) are well and do not require treatment. Indications for initiation of treatment in elderly patients are the same as in younger ones. Short cycles of treatment with chlorambucil in patients aged 66­82 years result in partial remission with good patient condition and satisfactory quality of life with chlorambucil maintenance therapy dura­ tion from 24 to 132 months (at the time this publication was prepared). More aggressive therapy (bendamustine + rituximab and fludarabine + cyclophosphamide) in patients aged 66­79 years is more efficient in terms of obtaining complete remission, but is more toxic and can be used in elderly patients who underwent comprehensive geriatric assessment with preserved renal function and absence of comorbidities.

Conclusions. Chlorambucil alone or combined with prednisone should be considered for the first­line therapy of CLL in elderly patients. More aggressive therapies (FC, BR regimens) should be applied at disease progression as treatment of the second line.

References

  1. Mulligan SP, Gill DS, Turner P, Renwick WEP, Harrup R, Latimer M et al. A randomized dose deescalation safety study of oral fludarabine, ± oral cyclophosphamide and intravenous rituximab (OFOCIR) as firstline therapy of Flt patients with chronic lymphocytic leukaemia (CLL) aged ≥ 65 years: end of recruitment analysis of response and toxicity of the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 study. Blood (ASH Annual Meeting Abstracts). 2012;120(21):436.
  2. Shanafelt TD, Rabe KG, Kay NE, Zent CS, Jelinek DF, Reinalda MS et al. Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. Cancer. 2010;116(20):4777-4787. https://doi.org/10.1002/cncr.25292
  3. Balducci L. ESH­SIOG international conference on haematological malignancies in the elderly. Expert Rev 2010;3(6):675-677. https://doi.org/10.1586/ehm.10.72
  4. Fischer K, Cramer P, Busch R, Böttcher S, Bahlo J, Schubert J et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012;30(26):3209-3216. https://doi.org/10.1200/JCO.2011.39.2688
  5. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220-241. https://doi.org/10.3322/caac.21149
  6. Shvidel L, Shtalrid M, Bairey O, Rahimi-Levene N, Lugassy G, Shpilberg O et al. Conventional dose fludarabine­based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2003;44(11):1947-1950. https://doi.org/10.1080/1042819031000110991
  7. Del Giudice I, Mauro F, Foà R. Chronic lymphocytic leukemia in less fit patients: ″slow­go″. Leuk Lymphoma. 2011;52(12):2207-2216. https://doi.org/10.3109/10428194.2011.606386
  8. Eichhorst B, Goede V, Hallek M. Treatment of elderly patients with chronic lymphocytic Leuk Lymphoma. 2009;50(2):171-178. https://doi.org/10.1080/10428190802688517
  9. Extermann M. Integrating a geriatric evaluation in the clinical setting. Semin Radiat Oncol. 2012;22(4):272-276. https://doi.org/10.1016/j.semradonc.2012.05.003
  10. Eichhorst BF, Busch R, Stilgenbauer S, Stauch M, Bergmann MA, Ritgen M et al. First­line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood. 2009;114(16):3382-3391. https://doi.org/10.1182/blood-2009-02-206185
  11. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343(24):1750-1757. https://doi.org/10.1056/NEJM200012143432402
  12. Foa R, Ciolli S, Di Raimondo F, Del Poeta G, Lauria F, Forconi F et al. A Phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: Results of the first interim analysis. Blood (ASH Annual Meeting Abstracts). 2010;116:2
  13. Goede V, Hallek M. Optimal pharmacotherapeutic management of chronic lymphocytic leukaemia: considerations in the elderly. Drugs Aging. 2011;28(3):163-176. https://doi.org/10.2165/11587650-000000000-00000
  14. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia: updating the National Cancer Institute­Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456. https://doi.org/10.1182/blood-2007-06-093906
  15. Hillmen P, Gribben JG, Follows GA, Milligan D, Sayala HA, Moreton P et al. Rituximab plus chlorambucil in patients with CD20positive Bcell chronic lymphocytic leukemia (CLL): Final response analysis of an openlabel Phase II study. Blood (ASH Annual Meeting Abstracts). 2010;116:697.
  16. Woyach JA, Ruppert AS, Rai K, Lin TS, Geyer S, Kolitz J et al. Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies. J Clin Oncol. 2013;31(4):440-447. https://doi.org/10.1200/JCO.2011.41.5646
  17. Guo B, Zhu HL, Fan H, Li SX, Lu XC, Lin J et al. Individualized fludarabine­based regimen in elderly patients with, chronic lymphocytic leukemia/small lymphocytic lymphoma. Adv Ther. 2012;29(2):178-186. https://doi.org/10.1007/s12325-011-0097-y
  18. Lamanna N. Treatment of older patients with chronic lymphocytic leukemia. Curr Hematol Malig 2012;7:21-25. https://doi.org/10.1007/s11899-011-0111-0
  19. Badoux XC, Keating MJ, Wen S, Lee BN, Sivina M, Reuben J et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood. 2011;118(13):3489-3498. https://doi.org/10.1182/blood-2011-03-339077
  20. Foon KA, Mehta D, Lentzsch S, Kropf P, Marks S, Lenzner D et al. Long­term results of chemoimmunotherapy with low dose fludarabine, cyclophosphamide and high­dose rituximab as initial treatment for patients with chronic lymphocytic leukemia. Blood. 2012;119(13):3184-3185. https://doi.org/10.1182/blood-2012-01-408047
  21. Goede V, Fischer K, Humphrey K, Asikanius E, Busch R, Engelke A et al. Obinutuzumab (GA101) plus chlorambucil (Clb) or rituximab (R) plus Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and preexisting medical conditions (comorbidities): Final Stage 1 results of the CLL11 (BO21004) phase III trial. J Clin Oncol. 2013;31:7004.
  22. Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009;27(26):4378-4384. https://doi.org/10.1200/JCO.2008.20.8389
  23. Castro JE, James DF, Sandoval-Sus JD, Jain S, Bole J, Rassenti L et al. Rituximab in combination with high­dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia. 2009;23(10):1779-1789. https://doi.org/10.1038/leu.2009.133
  24. Robak Chronic lymphocytic leukemia in older patients. Acta Haematologica Polonica. 2013;44:93-98.
  25. Routledge D, Bloor Recent advances in therapy of chronic lymphocytic leukaemia. Br J Haematol. 2016;174(3):351-367. https://doi.org/10.1111/bjh.14184
  26. Shanafelt Treatment of older patients with chronic lymphocytic leukemia: key questions and current answers. Hematology Am Soc Hematol Educ Program. 2013;2013:158-167.
  27. Smolej L. Therapy of elderly/comorbid patients with chronic lymphocytic leukemia. Curr Des. 2012;18(23):3399-3405. https://doi.org/10.2174/138161212801227096
  28. Terret Management and geriatric assessment of cancer in the elderly. Expert Rev Anticancer Ther. 2004;4(3):469-475. https://doi.org/10.1586/14737140.4.3.469
  29. Ferrajoli A, O’Brien S, Wierda W et al. Treatment of patients with CLL 70 years old and older: a single center experience of 142 patients. Leuk Lymphoma. 2005;46:48.